REZOLVE Trial

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant ovarian cancer

Trial Acronym: REZOLVE
Protocol Number: ANZGOG 1101

Key Question: To evaluate the activity of intraperitoneal (IP) bevacizumab to reduce the formation or delay the re-accumulation of malignant ascites (median time from first to second therapeutic ascitic drainage).

Trial Design: A single arm phase II study

ANZ Study Chairs: Prof Michael Friedlander and Dr Katrin Sjoquist

ANZ Coordinating Centre: NHMRC Clinical Trials Centre - University of Sydney

Trial Coordinator: Joe Levitt

Trial Email: rezolve@ctc.usyd.edu.au

Tumour Stream: Platinum resistant/refractory ovarian cancer, peritoneal or fallopian tube cancer with symptomatic ascites requiring therapeutic drainage.

Intervention: Administration of IP bevacizumab after a required therapeutic drainage of malignant ascites. There is no control group, all patients receive study drug. The aim is to see if there is a reduction or delay in the formation of the ascites.

Eligibility: The study is open to all women with the required cancers who are not receiving and are not planning to receive additional systemic chemotherapy. They must have required at least one therapeutic ascitic drainage within the last 4 weeks.

Status: Open to recruitment

Participating Sites: Go to the Clinical Trials section on www.anzgog.org.au